dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor (Brickell Biotech)

N/A

Report date: 2025/03/18 18:23:26

NME

Base Information

Drug Namedual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor (Brickell Biotech)

Drug Alias Namedual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor (Fresh Tracks Therapeutics)dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor (Voronoi)Next Generation DYRK1A inhibitor (Brickell Biotech)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionDual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors

TargetsDual-specificity tyrosine-phosphorylation regulated kinase 1A

Therapy Area/IndicationsAutoimmune Diseases +[2]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVoronoi Inc

China Registration ClassN/A

Develop Information

Active CompaniesFresh Tracks Therapeutics Inc

Inactive CompaniesVoronoi Inc

Active IndicationsAutoimmune Diseases +[2]

Inactive IndicationsN/A

Other Information

ATC CodeN/A